semaglutide addiction treatment as a promising new for alcohol use disorder semaglutide addiction AUD — Manhattan

However, its best to introduce one at a time to monitor effects

Gastrointestinal effects represent the most frequently reported adverse reactions, occurring in a substantial proportion of patients, particularly during treatment initiation and dose escalation: Nausea (very common, affecting more than 1 in 10 people) typically peaks during the first few weeks and often diminishes with continued treatment [1] [2] Diarrhoea (very common, affecting more than 1 in 10 people) Vomiting (common, affecting up to 1 in 10 people) Abdominal pain, constipation, and dyspepsia occur with variable frequency Reduced appetite is an expected pharmacological effect contributing to weight loss but may occasionally be excessive These gastrointestinal symptoms usually improve over time as the body adjusts to the medication

Adjuvant Therapy for Inflammatory Bowel Disease (IBD) Anti-inflammatory and mucosal repair BPC 157 can inhibit the release of pro-inflammatory cytokines (such as TNF- and IL-6) and alleviate intestinal inflammation

GLP-1 treatment for diabetes and obesity Semaglutide, a GLP-1 receptor agonist, is the active ingredient in Ozempic for diabetes and in Wegovy for obesity

Clinical trials have demonstrated that it can reduce the risk of major adverse cardiovascular events in people with type 2 diabetes

Improved Health Aids in the management of weight-related conditions